Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purified Vero Cell Rabies Vaccine (PVRV) is an inactivated biologic vaccine developed by Crucell Holland BV (a subsidiary of Janssen/Johnson & Johnson) for rabies prevention and post-exposure prophylaxis. The vaccine is produced by growing the Wistar strain of the rabies virus in Vero cell cultures, followed by inactivation with β-propiolactone and subsequent purification. It is designed to induce the production of rabies virus neutralizing antibodies (RVNA) to provide active immunity against infection. In clinical development, this specific PVRV formulation has been evaluated in Phase II trials (such as NCT01228383) both as a standalone vaccine and in combination with monoclonal antibody cocktails like CL184 to simulate post-exposure prophylaxis regimens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Purified Vero Cell Rabies Vaccine (Crucell).